Endocyte raises another $189M
Endocyte Inc., a West Lafayette-based biopharmaceutical company developing new cancer therapies, has raised $189 million after expenses through a public stock offering—its second of the year. The company said in September it closed on an offering of 10.8 million shares, including the full exercise of underwriters’ options. The shares were priced at $18.50. Endocyte said it intends […]